WHAT IS INDIEBIO NEW YORK

We are the world’s leading life sciences startup accelerator and community.
INDIEBIO IS PART OF A GLOBAL FAMILY OF ACCELERATORS BACKED BY SOSV

HARDWARE
- Connected devices
- Artificial intelligence and machine learning with sensors & robotics
- Medical devices

LIFE SCIENCES
- Future of Food
- Industrial biology
- Consumer biology
- Neurotech
- Computational biology
- Diagnostics
- Biopharma & Therapeutics

CROSS-BORDER INTERNET
- Blockchain
- Fintech
- E-commerce
- Education
- AI/ML
- SaaS
- Adtech

FOOD
- Foodtech
- Functional Foods
- Agriculture
- Distribution
- Inventory/Waste
What do we do?

WE TRANSFORM SCIENTISTS INTO ENTREPRENEURS

IndieBio enables the best scientists in the world to build radically transformative companies for human and planetary health.
Twice a year, early stage biology companies will move to NYC to take part in an intense four month program.

Founders engage with customers and partners, pitch to investors, and turn science into a real product people pay for.

Each team receives $250,000 in seed funding, lab and co-working space, and dedicated mentorship.

Alumni become part of a huge network of IndieBio alumni, investors, biotech entrepreneurs, investors, press, corporate partners, and more.
WE ARE HERE TO GROW NEW YORK BIOTECH COMPANIES

90% Of Teams have PhD/Postdocs as Founders

800 Attendees, each demo day

3,500 On-line viewers, each DD

>400 VCs/angels in attendance, 2019 Demo Days

30 # of Countries Founders came from

$2.5M Average Follow-on Funding raised For each successful startup

>700 Full-time Life Science Jobs created to date by IndieBio/RebelBio startups

80% Survival Rate (Teams still operating, 4 years in)
LIFE SCIENCES 2020 REAL ESTATE DEVELOPMENT SYMPOSIUM
Deepak Hegde

Deepak Hegde is the Founding Director of the Endless Frontier Labs, Director of the Berkley Center for Entrepreneurship and Associate Professor of Management at NYU Stern School of Business. Deepak’s research focuses on entrepreneurship and innovation. He studies how entrepreneurs and inventors in science and technology based industries overcome the challenges associated with commercializing their ideas. His work has been published in journals such as *Science, Journal of Finance and Management Science*, and featured in outlets such as *Nature, Harvard Business Review* and the *Wall Street Journal*. He was named Thomas Alva Edison Fellow at the U.S. Patent and Trademark Office and one of the world’s best 40 under 40 business school professors by *Poets & Quants*. Deepak earned his PhD in Business Economics from the University of California, Berkeley.
Herbert Boyer

Robert Swanson

= Genentech

Kleiner Perkins
The EFL Mission

To transform scientific breakthroughs into societal impact

The EFL Program

- 9-month program for science and technology based, seed-stage, startups
- Founder friendly, zero-fee zero equity
- Program open to startups all over the world

NYU Stern MBAs

Scientists + Business Experts

Startups

Investors

Corporate Partners
Visit https://endlessfrontierlabs.com/mentors/ for the full list of EFL mentors.
EFL Mentors (Investors)

Visit https://endlessfrontierlabs.com/mentors/ for the full list of EFL investor-mentors.
## EFL Highlights 2018 & 2019

**1,000+**  
Applicants

**45**  
Startup Graduates

**100+**  
Stern MBA Students

---

**$72M funds raised**  
by 34 startups since starting the EFL program

**$167M Equity Value**  
of 12 EFL graduates

---

**Life Sciences**

**Deep Tech**
“New frontiers of the mind are before us, and if they are pioneered with vision, boldness, and drive, we can create a more fruitful life.”

Vannevar Bush, *Science, The Endless Frontier*

*United States Office of Scientific Research and Development, July 1945*

✉️ : dh99@stern.nyu.edu

✨ : www.EndlessFrontierLabs.com
Biotech Grows in Brooklyn

Eva Cramer, PhD, President
Downstate Biotechnology Incubator, Tech @ 710, and BioBAT
Downstate Biotech Incubator
(Early-Stage Biotech/Tech Companies)
- 50,000 sf
  - Modular Lab & Office Space
  - Core Facility & Conference Space
- Nursery Program For Smaller Companies

Tech @ 710
(Specialized Chemistry Space and Offices)
- 13,000 sf
  - 6,400 sf Lab Space
  - 6,600 sf Office Space
- 26 Fume Hoods

BioBAT at the Brooklyn Army Terminal
(Biotech/Tech Research & Manufacturing Companies)
- Research & Manufacturing Space
  - Phase 1 – 38,000 sf, Phase 2 – 85,000 sf
- Joint Venture: SUNY Downstate & NYCEDC
- NYC Ferry Service

- Access to University Resources
  - Scientists / Clinicians / Students
  - Medical / Scientific Library
  - Vivarium / Research Facilities / Clinical Trials
- Entrepreneurship Programs
- Easy Access to NYC Research Institutions
### COMPANY SUCCESS¹

<table>
<thead>
<tr>
<th>Category</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Companies</td>
<td>38</td>
</tr>
<tr>
<td>Jobs</td>
<td>238</td>
</tr>
<tr>
<td>Increased Revenues</td>
<td>$5,589,117</td>
</tr>
<tr>
<td>Fed/Non-Gov’t Funds</td>
<td>$329,060,821</td>
</tr>
<tr>
<td>Patents (received &amp; filed)</td>
<td>22</td>
</tr>
</tbody>
</table>

¹ 4/1/19 – 3/31/20
² Includes purchase of Modis Therapeutics by Zogenix for $250,000,000
LIFE SCIENCES 2020 REAL ESTATE DEVELOPMENT SYMPOSIUM
NY State Center For Biotechnology

Mission: Increase the Yield, Accelerate Development, and Improve the Success Rate of Emerging Life Science Technologies and Companies Statewide
DESIGNATIONS

NYSTAR

NIH

REACH HUB

FOCUS AREAS

Tech Development & Company Formation

Strategic Partnerships

Capital Formation

Mentorship

Diversity, Inclusion

CENTER FOR BIOTECHNOLOGY
A New York State Center for Advanced Technology

Long Island Bioscience Hub

EDA

BARD

LIFE SCIENCES 2020 REAL ESTATE DEVELOPMENT SYMPOSIUM
Pipeline Development

Technology Development

- REACH: FEASIBILITY FUNDING $50k
- REACH: POC FUNDING $100k
- Long Island Innovation Boot camp/Pre-Seed Workshop

Company Formation/Support

- NEWCO CREATION BEIRS
- BIOMENTOR/ BIOSTRATEGY PROGRAM SUPPORT
- CONTINUED VENTURE SUPPORT TOWARD EXIT

Prepare for Funding

- SERIES A FINANCING

Logos:
- NIH
- REACH HUB
- NYSTAR
- EDA
- DRIVE
- Fundamentals of the Bioscience Industry
- LifeSciences Summit
• NIH REACH Hubs (Long Island, KY, MN, Midwest, NJ, CO, WA)
• NCAIs (Boston, Cleveland, U of CA med centers)
• Represents innovation capacity of 30+ academic institutions developing best practices for **pipeline development**.
• Federal Review Committee: NIH, USPTO, FDA, CMS, Kaiser Permanente
• External Review Board: (Pfizer, Lilly, Regeneron, Celdara, Bayer, ChemBio, OrbiMed, Canaan Ventures, Pappas Ventures, MPM Capital, Osage University Partners, Omega Funds)
Three Year Return on NIH REACH Investment
Jan 2016 – Dec 2019

REACH STATISTICS

<table>
<thead>
<tr>
<th>Proposals Received</th>
<th>187</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feasibility Funded</td>
<td>38</td>
</tr>
<tr>
<td>Proof of Concept Funded</td>
<td>20</td>
</tr>
<tr>
<td>Current Capital Committed</td>
<td>$3.8M</td>
</tr>
<tr>
<td>Licenced Technologies</td>
<td>3</td>
</tr>
<tr>
<td>Technologies optioned</td>
<td>4</td>
</tr>
<tr>
<td># of SBIR/STTR Funding grants awarded to REACH based ventures</td>
<td>8</td>
</tr>
<tr>
<td>Follow on Funding</td>
<td>$31.4M</td>
</tr>
</tbody>
</table>

Company Name | REACH support | Capital Raised Post REACH |
-------------|---------------|---------------------------|
Curemir      | $150,000      | $10,707,627.00            |
Point 7      | $100,000      | $236,016.00               |
Chronus      | $400,000      | $3,783,310.00             |
Marvel Genomics | $100,000  | $150,100.00               |
MicroRid     | $50,000       | $5,868,332.00             |
MapNeuro     | $100,000      | $100,000.00               |
Manhattan Biosolutions | $50,000 | $1,057,764.00 |

Figure 2 REACH Stats as of 12/31/2019

Figure 3 Successful ventures spun out stemming from REACH funding and resulting follow-on capital.
Entrepreneur
- Joseph Scaduto
- Reinhard Warnking
- Andreas Grill
- Michael Bielski
- Mohan Chellani
- Brian McCarthy
- Luca Araldi
- Derek Brand
- Boris Shor
- Peter Young
- William Mann

Startup
- Traverse Bioscience, Hairpin Tech
- Guided Interventions
- DepYMed
- Osteomedix, Hairpin Tech, PreSight Tech
- Progen Life Sciences
- MicroRid Technologies
- Avanti Biosciences
- Marvel Genomics
- Manhattan Biosciences
- Executive in Residence

$15M+ Leveraged Funding
• **BioStrategy Sessions:** 2 hour pitch sessions with feedback from industry and VC advisors.

• **Commercialization Clinic:** ip strategy, competitive landscaping, regulatory, strategic planning

**Supported By:**

[Brand Logos]
• Linda E. Amper, PhD, Chief People Officer at Clever Devices
• Gian Luca Araldi, PhD, Former Sr. Director, Forest Laboratories
• Kara Cannon, Global Head of Sales & Marketing, Enzo Life Sciences, Inc.
• Wayne Koff, PhD, President and CEO, Human Vaccines Project
• Jeff Peacock, VP Global QA and Regulatory Affairs, Henry Schein
• Saied Tousi, PhD, Managing Director, NW Advisors (former SVP Pall Corp)
• Edward Travaglianti, Market President of Long Island, TD Bank
• Peter Young, MBA, Executive-in-Residence, Pappas Capital
• Anil Dhundale, PhD, Former Exec Director, Long Island High Tech Incubator (LIHTI)
• Richard S. (Ric) Overton, Corp VP, Forest Laboratories
• Daniel Yarosh, PhD, Former Sr. VP, Estee Lauder
• Bob Williams, Principal, IV Matters
• Carl Pergola, Partner (retired), BDO
• Su Zhang, Strategy & External Scientific Affairs, Prizer
• Alfonso Higeura, Co-founder, Aztech Pharma
• Richard Catalano, Partner (retired), KPMG
- Awarded by EDA in Nov 2016
- $500K over 3 years to support mentoring and SBIR/STTR applications to NIH
- 2 ½ day workshop specific to NIH SBIR/STTR programs
- Followed by interactive instructional webinar and 1:1 iterative grant writing services.
- Ultimate goal to bring more $$ to Long Island & support company growth.

- 2020 Designation from Empire State Development as the: 
  *Downstate SBIR/STTR Training Hub* 
  (LI/NYC/Lower Hudson Valley)
DRIVE is seeking bold solutions. These include innovations focused on:
• clinical management strategies supported by enhanced education and awareness
• rapid diagnostics & prognostics
• continuous multi-dimensional patient monitoring
• machine learning-based disease management feedback algorithms
• optimized therapeutic interventions

**Early Notification to Act, Control, and Treat (ENACT)** leverages advanced data analytics and algorithms coupled with innovative detection modalities to accurately and quickly diagnose patients who have been exposed to pathogens and prognosticate outcomes. ENACT will close the gap between diagnosis and treatment by utilizing the power of telemedicine to bring clinical care into the home. The de-identified data from these individual signals will create real-time information for public health officials about outbreaks in communities.

DRIVE will seek a limited number of additional extremely bold, radical, and disruptive innovative solutions that will have the ability to transform health security. These include – but are not limited to – creating universal treatment options for broad classes of pathogens, ensuring access to life-saving medical countermeasures, and transforming medical countermeasure development by eradicating animal testing.
• 86-hour training program provides grad students, post-doc, and early stage professional with holistic overview of biomedical commercialization
• Fully taught by industry veterans in the biomedical space
• Hands-on experience with technology and business strategy
• Final presentation to investors and advisors
• 500+ grads of the program pursuing law, BD, management consulting, finance, entrepreneurship, etc.
Sponsors and Partners

EisnerAmper
Stony Brook University
COVINGTON
sartorius stedim

Paul Hastings
Solebury Trout

MERCK
Nixon Peabody

Wilson Sonsini Goodrich & Rosati
professional corporation

Definitive Health

Defined Health

myBio

Defined Health

New York University

Exokine Institute for Medical Research
<table>
<thead>
<tr>
<th>Li &amp; NYC Clients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ortek Therapeutics, Inc.</td>
</tr>
<tr>
<td>Allovate</td>
</tr>
<tr>
<td>Alpha-1 Biologics Corporation</td>
</tr>
<tr>
<td>Anschel Technology, Inc.</td>
</tr>
<tr>
<td>Applied DNA Sciences</td>
</tr>
<tr>
<td>Avanti Biosciences</td>
</tr>
<tr>
<td>Avery Biomedical</td>
</tr>
<tr>
<td>CardiaTouch Control Systems</td>
</tr>
<tr>
<td>Certerra, Inc.</td>
</tr>
<tr>
<td>Chronus Pharma</td>
</tr>
<tr>
<td>Codagenix, Inc.</td>
</tr>
<tr>
<td>CuraMir</td>
</tr>
<tr>
<td>DepYMed</td>
</tr>
<tr>
<td>EnvisaGenics, Inc</td>
</tr>
<tr>
<td>Enzo Life Sciences, Inc</td>
</tr>
<tr>
<td>ET Medical</td>
</tr>
<tr>
<td>ExVivo Dynamics</td>
</tr>
<tr>
<td>Glia llc</td>
</tr>
<tr>
<td>Harbor Innovations</td>
</tr>
<tr>
<td>iCell Gene Therapeutics</td>
</tr>
<tr>
<td>ImmunoMatrix</td>
</tr>
<tr>
<td>Immunovent</td>
</tr>
<tr>
<td>inGenious Targeting Laboratory (iTL)</td>
</tr>
<tr>
<td>Kantian Sciences Corp.</td>
</tr>
<tr>
<td>Manhattan Biosolutions</td>
</tr>
<tr>
<td>MedAux</td>
</tr>
<tr>
<td>MicroRid</td>
</tr>
<tr>
<td>NangioTX</td>
</tr>
<tr>
<td>NeoMatrix Therapeutics, LLC (formerly NeoMatrix Formulations)</td>
</tr>
<tr>
<td>NomoCan Pharmaceuticals</td>
</tr>
<tr>
<td>Pepper5</td>
</tr>
<tr>
<td>PhD Biosciences (formerly Nanometrics, LLC)</td>
</tr>
<tr>
<td>PolyNova Cardiovascular</td>
</tr>
<tr>
<td>RGenix</td>
</tr>
<tr>
<td>S.A.L.T.</td>
</tr>
<tr>
<td>Simulon</td>
</tr>
<tr>
<td>Stony Brook University, Office of Technology Licensing and Industry Relations</td>
</tr>
<tr>
<td>Sustained Nano Systems, Inc.</td>
</tr>
<tr>
<td>Symbiotic Health</td>
</tr>
<tr>
<td>SynchroPET, LLC</td>
</tr>
<tr>
<td>TargaGenix</td>
</tr>
<tr>
<td>Theragnostics Technologies</td>
</tr>
<tr>
<td>TheraSource, LLC</td>
</tr>
<tr>
<td>Traverse Biosciences, Inc.</td>
</tr>
<tr>
<td>Vascular Simulations</td>
</tr>
<tr>
<td>Vela Therapeutics</td>
</tr>
<tr>
<td>Venus Pharmaceuticals</td>
</tr>
<tr>
<td>VitalVio</td>
</tr>
<tr>
<td>AB Bioinnovations</td>
</tr>
<tr>
<td>ABMM</td>
</tr>
<tr>
<td>Ajes Life Sciences</td>
</tr>
<tr>
<td>ALA Scientific</td>
</tr>
<tr>
<td>Archegos Biomedical (Bill Hanes)</td>
</tr>
<tr>
<td>Biocogent</td>
</tr>
<tr>
<td>CRAWS Cell Therapy</td>
</tr>
<tr>
<td>Daxor</td>
</tr>
<tr>
<td>Grit Bio</td>
</tr>
<tr>
<td>Hesperos</td>
</tr>
<tr>
<td>Ichor Biologics</td>
</tr>
<tr>
<td>Incysus</td>
</tr>
<tr>
<td>Intrellit</td>
</tr>
<tr>
<td>Lucerna</td>
</tr>
<tr>
<td>MapNeuro</td>
</tr>
<tr>
<td>Marvel Genomics</td>
</tr>
<tr>
<td>Mitani Group</td>
</tr>
<tr>
<td>Plico</td>
</tr>
<tr>
<td>Quentis</td>
</tr>
<tr>
<td>RDS2 Solutions, Inc.</td>
</tr>
<tr>
<td>Rumi</td>
</tr>
<tr>
<td>Vesen?</td>
</tr>
<tr>
<td>Progen Life Sciences</td>
</tr>
<tr>
<td>Biodex</td>
</tr>
<tr>
<td>OsteoMedix</td>
</tr>
<tr>
<td>Presight Technologies</td>
</tr>
<tr>
<td>Hairpin Technologies</td>
</tr>
</tbody>
</table>
$1.2B
Economic Impact

$35M
Corp Savings

$238M
Funds Leveraged

$812M
New Corp Revenues

1125
Jobs Created
Thank you,
NYC Builds Bio!

Questions?
LIFE SCIENCES

2020 REAL ESTATE DEVELOPMENT SYMPOSIUM

NYC BUILDS BIO+
We catalyze the creation of high-quality, cutting edge life science companies.

We provide a complete business, scientific, and financial toolkit to support new life science company formation:

<table>
<thead>
<tr>
<th>VENTURE CAPITAL</th>
<th>EXPERIENCED MANAGEMENT TEAM</th>
<th>SCIENTIFIC EXPERTISE</th>
<th>TURN-KEY FACILITIES</th>
</tr>
</thead>
<tbody>
<tr>
<td>from top-tier investors</td>
<td>with exceptional track record of building and exiting successful companies</td>
<td>and technical support to enhance oversight and management of operations</td>
<td>to meet unique needs of diverse life science start-up companies</td>
</tr>
</tbody>
</table>
Our model brings together a small group of engaged strategic stakeholders to source, evaluate, and form NEWCOs focused on commercializing promising, early-stage science.

ACCELERATOR & STAKEHOLDER(S)
Source promising investment opportunities

ACCELERATOR TEAM
Diligence opportunities, forms NEWCO and manages product development

BOARD (INVESTMENT COMMITTEE)
Approve new investments and provide critical insights to shape key product development milestones

ACCELERATOR TEAM & BOARD
Executive oversight and operational support for NEWCOS in parallel
LIFE SCIENCES
2020 REAL ESTATE DEVELOPMENT SYMPOSIUM
NYC BUILDS BIO+
Seeds of Success: Factors Fostering the Growth of Life Sciences Incubators and Accelerators in New York City

Alex Philippidis
Senior News Editor
Genetic Engineering & Biotechnology News (GEN)
October 29, 2020
• Launched 1981 by Mary Ann Liebert; 1st publication devoted exclusively to biotech field and remains the key driver in the explosion of the industry

• Key reader segments are R&D researchers, lab managers, bioprocess development scientists and executive management - including 65,000 qualified magazine subscribers; 180,000 Newsletter subscribers; 230,000 monthly website visitors

• GEN delivers critical, high-quality reporting in Bioprocessing, Cancer, Drug Discovery, OMICs, Translational Medicine, Genome Editing
New York City anchors a region that has grown **from 5th to 3rd** in GEN's annual ranking of Top 10 U.S. Biopharma Clusters.
GEN Ranks Regions on Five Criteria

1. **NIH funding**—Taken from the publicly available NIH RePORT database.

2. **VC funding**—Taken from the publicly available PwC/CB Insights MoneyTree™ Report.

3. **Patents**—Based on the number of patents containing the word “biotechnology” awarded since 1976 in cities and suburbs where key companies are located.

4. **Lab space**—Based on total-size-of-market figures, in millions of square feet, furnished by JLL, CBRE, Cushman & Wakefield, and Newmark Knight Frank.

5. **Jobs**—Based on JLL’s report and figures provided by regional groups.
Putting the Pieces Together

- Research Institutions
  - NIH Funding
  - Patents
- Investors
  - Venture Capital
- Governments
  - Incentives
- Real Estate Developers
  - Lab Space
  - Jobs
NYC institutions attract more basic research funding

• **FY 2020:**
  - $236,552,705 in funding
  - 350 awards

• **FY 2013:**
  - $152,250,110 in funding
  - 321 awards
Patents: More than Quadruple

Cumulative number of “biotechnology” patents awarded since 1976 has more than quadrupled:

- **2020:**
  - 3,044 patents

- **2013:**
  - 705 patents
Pandemic's Tragic Toll

As of October 23, according to Center for Systems Science and Engineering at Johns Hopkins U. and NYC Department of Health & Mental Hygiene:

**DEATHS:**
- 1,139,296 worldwide
- 19,315 in New York City *

**CONFIRMED CASES:**
- 43,174,685 worldwide
- 252,648 in New York City

* Does not include 4,654 "probable deaths" for which the cause was reported as "COVID-19" or equivalent, without a positive lab test (NIAID)
Worldwide Response by Industry, Academia

• 300+ Vaccines and Drugs in Development vs. COVID-19

• GEN COVID-19 DRUG & VACCINE TRACKER
Green New Deals

Investors pour capital into life sciences startups as city and state invest a combined $1.1 billion in incentives since 2016.
Venture Capital: Speeding Up, Slowing Down

Doubled Q1-Q3 2020 vs. a year ago, but losing steam due to COVID-19, after quintupling from 2013-2019

- **2020 (Q1-Q3):**
  - $1,415,470,000, 43 awards

- **2019**
  - **Q1-Q3:** $708,090,000 30 awards
  - **Year:** $2,199,830,000, 43 awards

- **2013**
  - $398,410,000, 26 awards

PWC MoneyTree Report, compiled with CB Insights
NYS: $620M Life Science Initiative

- $320 million = Development of wet-lab and innovation space, support operations, early-stage capital... With $100 million in private matching funds

- $100 million = “Excelsior Jobs Program” refundable tax credits

- $100 million toward life-sci R&D tax credit

- Online: https://esd.ny.gov/industries/biotech-and-life-sciences

JLABS@NYC: $17 million from NY State
NYC: $500M LifeSciNYC

- $320 million in tax incentives toward commercial lab space for life-sci businesses
- $100 million Applied Life Sciences campus planned
- $50 million for academic med centers, research facilities
- $20 million

Online: https://lifesci.nyc/

345 Park Avenue South: $92 million from NYC Economic Development Corp.
Space Race

Developers, owners, and others address demand for life sciences "location, location, location"
Lab Space: More than Doubling

- 2013: 1.7 million square feet

- **2020:** 2.1 million square feet

- ... with 2.5 million square feet under construction or planned
  - Alexandria Real Estate Equities: NYC, LIC, and Pfizer HQ
  - Deerfield Management
  - Harlem Biolabs
  - Silverstein Properties
  - Taconic Partners / Nuveen
  - Taystee Lab Building

Clockwise from top left: Alexandria Real Estate Equities’ Alexandria Centers in Manhattan and Long Island City; Deerfield Management’s 345 Park Avenue South [RFR]
Employment: Rising Trend

Employment has risen in recent years, though numbers vary

• **2020:**
  - Figures range from over 65,601 (JLL), to more than 75,000 (NewYorkBIO)

• **2013**
  - 60,000+, NYC EDC reported at the time
Introducing Today's Panelists:

• Stephen Chambers, PhD, New York Partner and Managing Director, IndieBio NY

• Deepak Hegde, PhD, Director at Endless Frontier Labs, NYU Stern School of Business

• Nishta Rao, MBA, Managing Director, First Republic Bank; BioLabs@NYU

• Samuel K. Sia, PhD, Co-Founder, Harlem Biospace
Introducing Today's Panelists:

- **Eva B Cramer, PhD**, Vice President for Biotechnology and Scientific Affairs, SUNY Downstate Biotechnology Incubator
- **Diane Fabel, MS**, Director of Operations, Center for Biotechnology, Stony Brook University
- **Alice Chen, PhD**, Vice President, Accelerator Life Science Partners (ALSP)
- **Cynthia Cleto, MS**, Director, Outreach, Entrepreneurship and Special Programs, Mount Sinai Innovation Partners
Thanks for viewing. Let’s stay in touch!

• Alex Philippidis
  • Email: aphilippidis@liebertpub.com
  • Twitter: @AlexWestchester
  • Phone: (914) 740-2245